Literature DB >> 16432296

Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension.

Noriyuki Homma1, Yoshiteru Morio, Hideki Takahashi, Akihito Yamamoto, Tsutomu Suzuki, Koichi Sato, Masashi Muramatsu, Yoshinosuke Fukuchi.   

Abstract

BACKGROUND: Pulmonary hypertension is characterized by high pulmonary blood pressure, vascular remodeling, and right ventricular hypertrophy. Although recent studies suggest that an imbalance between endothelial mediators on pulmonary vasculature may contribute to the development of pulmonary hypertension, the pathogenesis is not fully understood and the treatment of pulmonary hypertension is still unresolved.
OBJECTIVE: The purpose of this study was to investigate whether genistein, a phytoestrogen derived from soybean, would prevent the development of monocrotaline (MCT)-induced pulmonary hypertension in rats. Hemodynamic parameters of catheterized rats and morphological feature of lungs were evaluated among MCT-treated rats receiving or not receiving genistein. Furthermore, examination of expression in endothelial nitric oxide synthase and endothelin-1 peptide level was performed.
METHODS: Daily supplementation with either genistein (0.2 mg/kg) or vehicle was started 2 days prior to a single-dose injection of MCT (60 mg/kg). On day 28, rats underwent catheterization, and right ventricular hypertrophy and morphological features were assessed. Furthermore, endothelial nitric oxide synthase and endothelin-1 were examined by Western blot analysis and radioimmunoassay, respectively, in homogenated lungs.
RESULTS: In rats that received daily supplementation of genistein, mean pulmonary arterial pressure was significantly reduced, whereas mean systemic arterial pressure and heart rate were unaltered compared with MCT control rats on day 28 after MCT injection. Right ventricular hypertrophy, medial wall thickness of pulmonary arteries corresponding to the terminal bronchioles, and the degree of neo-muscularization of more distal arteries were less severe in genistein-treated rats. Genistein supplementation improved MCT-induced downregulation of expression of endothelial nitric oxide synthase in the lungs. However, endothelin-1 peptide levels did not differ among all groups of lungs.
CONCLUSIONS: We conclude that daily supplementation of genistein potently attenuates MCT-induced pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular remodeling in rats. The underlying mechanism responsible for this effect may be partly related to the restoration of a decreased expression of endothelial nitric oxide synthase. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16432296     DOI: 10.1159/000088946

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  9 in total

1.  Estrogen rescues preexisting severe pulmonary hypertension in rats.

Authors:  Soban Umar; Andrea Iorga; Humann Matori; Rangarajan D Nadadur; Jingyuan Li; Federica Maltese; Arnoud van der Laarse; Mansoureh Eghbali
Journal:  Am J Respir Crit Care Med       Date:  2011-06-23       Impact factor: 21.405

2.  Intralipid prevents and rescues fatal pulmonary arterial hypertension and right ventricular failure in rats.

Authors:  Soban Umar; Rangarajan D Nadadur; Jingyuan Li; Federica Maltese; Parisa Partownavid; Arnoud van der Laarse; Mansoureh Eghbali
Journal:  Hypertension       Date:  2011-07-11       Impact factor: 10.190

Review 3.  Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease.

Authors:  Stevan P Tofovic
Journal:  J Cardiovasc Pharmacol       Date:  2010-12       Impact factor: 3.105

4.  Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats.

Authors:  Humann Matori; Soban Umar; Rangarajan D Nadadur; Salil Sharma; Rod Partow-Navid; Michelle Afkhami; Marjan Amjedi; Mansoureh Eghbali
Journal:  Hypertension       Date:  2012-07-02       Impact factor: 10.190

Review 5.  Novel approaches to treat experimental pulmonary arterial hypertension: a review.

Authors:  S Umar; P Steendijk; D L Ypey; D E Atsma; E E van der Wall; M J Schalij; A van der Laarse
Journal:  J Biomed Biotechnol       Date:  2010-03-22

Review 6.  Estrogen paradox in pulmonary hypertension: current controversies and future perspectives.

Authors:  Soban Umar; Marlene Rabinovitch; Mansoureh Eghbali
Journal:  Am J Respir Crit Care Med       Date:  2012-05-03       Impact factor: 21.405

7.  Determination of the effects of pulmonary arterial hypertension and therapy on the cardiovascular system of rats by impedance cardiography.

Authors:  Belgin Buyukakilli; Serkan Gurgul; Derya Citirik; Olgu Hallioglu; Murat Ozeren; Bahar Tasdelen
Journal:  Croat Med J       Date:  2014-10       Impact factor: 1.351

Review 8.  Impact of Nutrition on Pulmonary Arterial Hypertension.

Authors:  María Callejo; Joan Albert Barberá; Juan Duarte; Francisco Perez-Vizcaino
Journal:  Nutrients       Date:  2020-01-07       Impact factor: 5.717

Review 9.  Medicinal Plants and Phytochemicals for the Treatment of Pulmonary Hypertension.

Authors:  Seyed Vahid Jasemi; Hosna Khazaei; Ina Yosifova Aneva; Mohammad Hosein Farzaei; Javier Echeverría
Journal:  Front Pharmacol       Date:  2020-03-12       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.